sacubitril; valsartan
sacubitril; valsartan: sourced relationships with 1 company · 1 clinical trial tracked · 2 FDA decisions.
sacubitril; valsartan evidence translation
What we can confirm
2 FDA records · 1 tracked trial
What it means
What to watch
Prepared research question
How could sacubitril; valsartan → NVS affect its developer, and what evidence supports the link?
Traceable citations · Unknowns marked
See linked entities and source evidence1 indications · 0 study sponsors
Related indications
Study sponsors
No additional listed-company sponsor is linked.
Dated Pipeline Records (1)
| Company | Dated record stage |
|---|---|
| Novartis AG (NVS) Reported 2024-04-12 · Current development: unknownSource | Approved |
Clinical Trial Registry Records (1)
Special Drug Use Surveillance of Entresto Tablets (Hypertension, CLCZ696A1402): ENLIGHT
Primary endpoint: Percentage of patients with hypotension, hyperkalemia, and renal impairment/failure
FDA Decisions2 records
Frequently asked questions
Which companies have sourced relationships with sacubitril; valsartan?
sacubitril; valsartan has dated SEC/FDA relationship records for Novartis AG.
How many clinical trials involve sacubitril; valsartan?
BioSniper tracks 1 clinical trial involving sacubitril; valsartan.
What is sacubitril; valsartan's latest FDA decision?
The most recent tracked FDA decision for sacubitril; valsartan is Approval, dated April 12, 2024.